ZIOPHARM oncology names Hagop Youssoufian CMO
This article was originally published in Scrip
Executive Summary
ZIOPHARM Oncology, a drug development company employing small molecule and synthetic biology approaches to cancer therapy, has appointed Dr Hagop Youssoufian executive vice-president and chief medical officer, reporting to Dr Jonathan Lewis, ZIOPHARM's CEO. Dr Youssoufian has nearly 30 years' experience with companies such as Bristol-Myers Squibb, Sanofi-Aventis and, most recently, ImClone Systems.